3CON, founded 1998 and headquartered in Austria, with subsidiaries in USA, Mexico and China, is one of the global forerunners in the development of highly automated interior and plastic exterior production systems for the leading automotive industry.
With the Business Unit Pharma & Medical, 3CON has pioneered a patent-pending method to inactivate RNases. This method provides a unique solution to inhibit RNases in single-use bioprocess containers and single-use assemblies by Nonthermal Plasma. Furthermore, 3CON provides semi- and fully automated production solutions for 2D- & 3D-single-use bioprocess containers.
AT